ArticleInternational journal of experimental pathology2018
Association of miR-1247-5p expression with clinicopathological parameters and prognosis in breast cancer.
Article in International journal of experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Prediction of lymphocyte-predominant breast cancer using microRNA expression in cytology specimens.Cancer cytopathology · 2026Article
- Status Epilepticus Alters the Function of Brain-Derived Extracellular Vesicles.Journal of extracellular vesicles · 2026Article
- Stemness genes and miR-1247-3p expression associate with clinicopathological parameters and prognosis in lung adenocarcinoma.PloS one · 2023Article
- miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance.Journal of Cancer · 2022Article
- Decreased microRNA-768-3p expression indicates a poor prognosis in patients with breast cancer and promotes breast cancer cell viability, migration and invasion.Oncology letters · 2021Article
- Plasma miR-1247-5p, miR-301b-3p and miR-105-5p as potential biomarkers for early diagnosis of non-small cell lung cancer.Thoracic cancer · 2021Article
- Identification of MicroRNAs as Diagnostic Biomarkers for Breast Cancer Based on the Cancer Genome Atlas.Diagnostics (Basel, Switzerland) · 2021Article
- Comprehensive transcriptomic analysis of papillary thyroid cancer: potential biomarkers associated with tumor progression.Journal of endocrinological investigation · 2020Article
- Article
- Prognostic role of microRNAs in breast cancer: A systematic review.Oncotarget · 2019Article
- Association of miR-1247-5p expression with clinicopathological parameters and prognosis in breast cancer.International journal of experimental pathology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our study aimed to clarify the correlation between miR-1247-5p expression and clinicopathological parameters and survival of patients with breast cancer (BC). We evaluated the expression level of miR-1247-5p in 224 formalin-fixed, paraffin-embedded specimens (112 BC and matched cancer free tissues) by quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR). miR-1247-5p expression in BC tissues was found to be decreased compared with matched normal tissues (P < 0.01). Additionally, low miR-1247-5p expression in BC tissues was significantly associated with the advanced TNM stage (P = 0.007), lymph node metastasis (P = 0.015), poorer pathological differentiation (P = 0.005) and molecular subtype (P = 0.027). The patients in the low miR-1247-5p group had a shorter disease-free survival and overall survival than those in the high miR-1247-5p group (P < 0.01). Furthermore, the univariate and the multivariate analyses showed that miR-1247-5p expression was an independent predictor of overall survival (P < 0.01). Our study showed that miR-1247-5p was related to the biological behaviour of breast tumour and prognosis of patients with BC. miR-1247-5p could be a novel tumour suppressor and act as a potential biomarker and therapeutic agent for breast carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.